The DOI matches its Crossref record.
Abstract 44: The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer
Abstract
ARV-471, an estrogen receptor (ER) alpha PROTAC® protein degrader, is a hetero-bifunctional molecule that facilitates the interactions between estrogen receptor alpha and an intracellular E3 ligase complex, leading to the ubiquitylation and subsequent degradation of estrogen receptors via the proteasome. ARV-471 robustly degrades ER in ER-positive breast cancer cell lines with a half-maximal degradation concentration (DC50) of ~ 1 nM. PROTAC® mediated ER degradation decreases the expression of classically regulated ER-target genes and inhibits cell proliferation of ER-dependent cell lines (MCF7, T47D). Additionally, ARV-471 degrades clinically relevant ESR1 variants (Y537S and D538G) and inhibits growth of cell lines expressing those variants. In an immature rat uterotrophic model, ARV-471 degrades rat uterine ER and demonstrates no agonist activity. Daily, oral-administration of single agent ARV-471 (3, 10, and 30 mpk) leads to significant anti-tumor activity of estradiol-dependent MCF7 xenografts and concomitant tumor ER protein reductions of >90% at study termination. Moreover, when a CDK4/6 inhibitor is combined with ARV-471 in the MCF7 model, even more pronounced tumor growth inhibition is observed (131% TGI), accompanied by significant reductions in ER protein levels. In an ESR1 Y537S, hormone-independent patient-derived xenograft model, ARV-471 at 10 mpk completely inhibited growth and also significantly reduced mutant ER protein levels. Taken together, the preclinical data of ARV-471 supports its continued development as a best-in-class oral ER PROTAC® protein degrader. These preclinical data supported the clinical development of ARV-471 for the treatment of patients with breast cancer. The discovery, chemical structure and initial clinical data of ARV-471 will be presented. Citation Format: Lawrence B. Snyder, John J. Flanagan, Yimin Qian, Sheryl M. Gough, Monica Andreoli, Mark Bookbinder, Gregory Cadelina, John Bradley, Emma Rousseau, Julian Chandler, Ryan Willard, Jennifer Pizzano, Craig M. Crews, Andrew P. Crew, John Houston, Marcia Dougan Moore, Ron Peck, Ian Taylor. The discovery of ARV-471, an orally bioavailable estrogen receptor degrading PROTAC for the treatment of patients with breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 44.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The interim data for ARV-471 revealed a manageable tolerability profile with robust signals of clinical efficacy41, a 42% clinical benefit rate in a heavily pretreated population and evidence of better ER degradation than fulvestrant and other clinical-stage selective ER degraders (SERDs) when compared at the same stage of development.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [41]
In the citing paper
“The interim data for ARV-471 revealed a manageable tolerability profile with robust signals of clinical efficacy41, a 42% clinical benefit rate in a heavily pretreated population and evidence of better ER degradation than fulvestrant and other clinical-stage selective ER degraders (SERDs) when compared at the same stage of development.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [41]
In the citing paper
“The interim data for ARV-471 revealed a manageable tolerability profile with robust signals of clinical efficacy41, a 42% clinical benefit rate in a heavily pretreated population and evidence of better ER degradation than fulvestrant and other clinical-stage selective ER degraders (SERDs) when compared at the same stage of development.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [41]
In the citing paper
“Recently, it was disclosed that both ARV-110 and ARV-471 use CRBN as the E3 ligase that is recruited to their respective targets, AR and ER, to catalyse their ubiquitylation and proteasomal degradation41,71.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [41]
Citations
Cited by
Sorted by citations
PROTAC targeted protein degraders: the past is prologue
Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395
Self-citationProtein degraders enter the clinic — a new approach to cancer therapy
Chirnomas, D., Hornberger, K. R., & Crews, C. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00736-3 · Cited by 658
Self-citationAdvancing targeted protein degradation for cancer therapy
Dale, B., Cheng, M., Park, K., Kanıskan, H. Ü., Xiong, Y., & Jin, J. J. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00365-x · Cited by 697
Targeted protein degradation: advances in drug discovery and clinical practice
Zhong, G., Chang, X., Xie, W., & Zhou, X. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02004-x · Cited by 326
Gough, S. M., Flanagan, J. J., Teh, J. L. F., Andreoli, M., Rousseau, E., Pannone, M., Bookbinder, M., Willard, R. R., Davenport, K., Bortolon, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3465 · Cited by 219
“PROteolysis-TArgeting Chimera (PROTAC) molecules are a novel class of therapies being developed for cancer treatment and other life-threatening diseases driven by the aberrant expression of a disease-causing protein (1–5).”
BackgroundSelf-citationHuppert, L. A., Gümüşay, Ö., Idossa, D. W., & Rugo, H. S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21777 · Cited by 188
“prior CDK4/6 inhibitors and investigational oral SERDS, the CBR was 42%.(169) In the VERITAC phase 2 expansion trial (ClinicalTrials.”
Self-Assembled Nano-PROTAC Enables Near-Infrared Photodynamic Proteolysis for Cancer Therapy
Wang, W., Zhu, C., Zhang, B., Feng, Y., Zhang, Y., & Li, J. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.3c04109 · Cited by 152
Lloyd, M. R., Wander, S. A., Hamilton, E. P., Razavi, P., & Bardia, A. (2022) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221113694 · Cited by 124
Targeting the Estrogen Receptor for the Treatment of Breast Cancer: Recent Advances and Challenges
Rej, R. K., Thomas, J. E., Acharyya, R. K., Rae, J. M., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00136 · Cited by 117
Structural and Physicochemical Features of Oral PROTACs
Schade, M., Scott, J. S., Hayhow, T. G., Pike, A., Terstiege, I., Ahlqvist, M. M., Johansson, J. R., Diène, C. R., Fallan, C., Balazs, A., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01017 · Cited by 82
Current advances and development strategies of orally bioavailable PROTACs
Zeng, S., Ye, Y., Xia, H., Min, J., Xu, J., Wang, Z., Pan, Y., Zhou, X., & Huang, W. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115793 · Cited by 91
Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer
Lloyd, M. R., Jhaveri, K. L., Kalinsky, K. M., Bardia, A., & Wander, S. A. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00935-6 · Cited by 82
Advancing targeted protein degradation for metabolic diseases therapy
Zhou, Q., Xiao, H., Yang, F., Wang, Y., Li, P., & Zheng, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106627 · Cited by 77
Targeted Protein Degradation: Advances, Challenges, and Prospects for Computational Methods
Mostofian, B., Martin, H., Razavi, A. M., Patel, S., Allen, B. K., Sherman, W., & Izaguirre, J. A. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c00603 · Cited by 70
Advancing Strategies for Proteolysis-Targeting Chimera Design
Li, M., Zhi, Y., Liu, B., & Yao, Q. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01555 · Cited by 78
PROTACs: A novel strategy for cancer drug discovery and development
Han, X., & Sun, Y. (2023) · MedComm · doi:10.1002/mco2.290 · Cited by 69
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future
Li, R., Liu, M., Yang, Z., Li, J., Gao, Y., & Tan, R. (2022) · Molecules · doi:10.3390/molecules27248828 · Cited by 69
“ARV471 is currently in phase II clinical trials as a single agent for advanced metastatic breast cancer, and a phase Ib study has been initiated to evaluate the combination of ARV-471 with the CDK4/CDK6 agent palbociclib in advanced metastatic breast cancer [4].”
BackgroundInfluentialNovel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
Corti, C., Angelis, C. D., Bianchini, G., Malorni, L., Giuliano, M., Hamilton, E. P., Jeselsohn, R. M., Jhaveri, K. L., Curigliano, G., & Criscitiello, C. (2023) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2023.102569 · Cited by 64
E3 ligase ligand optimization of Clinical PROTACs
Jiang, H., Xiong, H., Gu, S.-X., & Wang, M. (2023) · Frontiers in Chemistry · doi:10.3389/fchem.2023.1098331 · Cited by 64
“Arvinas is the first company to clinically implement two PROTAC degraders, the androgen receptor (AR) degrader ARV-110 and the estrogen receptor (ER) degrader ARV-471 (Mullard, 2019).”
BackgroundInfluentialZou, Z., Yang, L., Nie, H., Gao, J., Lei, S., Lai, Y., Zhang, F., Wagner, E., Yu, H., Chen, X., et al. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01266-z · Cited by 65
Design and Synthesis of Novel Cereblon Binders for Use in Targeted Protein Degradation
Norris, S. H., Ba, X., Rhodes, J., Huang, D., Khambatta, G., Buenviaje, J., Nayak, S. K., Meiring, J., Reiss, S. M., Xu, S., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01848 · Cited by 61
Zhong, Y., Chi, F., Wu, H., Liu, Y., Xie, Z., Huang, W., Shi, W., & Qian, H. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114142 · Cited by 52
Zhang, Y., Gu, W., Chen, W., Zhu, J., Fan, L., Zhang, L., Zhao, L., & Miao, Q. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.4c18398 · Cited by 46
Drugtamer‐PROTAC Conjugation Strategy for Targeted PROTAC Delivery and Synergistic Antitumor Therapy
He, S., Fang, Y., Zhu, Y., Ma, Z., Dong, G., & Sheng, C. (2024) · Advanced Science · doi:10.1002/advs.202401623 · Cited by 46
Xie, B., Yin, Z., Hu, Z., Lv, J., Du, C., Deng, X., Huang, Y., Li, Q., Huang, J., Liang, K., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c02032 · Cited by 39
Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation
Jung, H., & Lee, Y. (2025) · Cancers · doi:10.3390/cancers17111871 · Cited by 41
“ARV-471 has shown promising efficacy in effectively degrading the estrogen receptor and reducing tumor size, both as a monotherapy and in combination with CDK4/6 inhibitors [59,60].”
The clinical advances of proteolysis targeting chimeras in oncology
Xie, H., Liu, J., Alem, D., & Fleming, J. B. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00061 · Cited by 38
Strategies for Precise Modulation of Protein Degradation
He, S., Dong, G., & Sheng, C. (2025) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5c00003 · Cited by 42
A novel ROR1-targeting antibody-PROTAC conjugate promotes BRD4 degradation for solid tumor treatment
Wang, L., Ke, Y., He, Q., Paerhati, P., Zhuang, W., Yue, Y., Liu, J., Zhang, J., Huang, L., Yin, Q., et al. (2024) · Theranostics · doi:10.7150/thno.102531 · Cited by 38
Ferro, A., Campora, M., Caldara, A., Lisi, D. D., Lorenzi, M., Monteverdi, S., Mihai, R., Bisio, A., Dipasquale, M., Caffo, O., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13123611 · Cited by 31
“Vepdegestrant (ARV-471) is a first-in-class molecule that has demonstrated superior ER degradation and antitumor activity compared to fulvestrant in endocrine-sensitive and -resistant xenograft models [165].”
BackgroundA comprehensive review of emerging approaches in machine learning for de novo PROTAC design
Gharbi, Y., & Mercado, R. (2024) · Digital Discovery · doi:10.1039/d4dd00177j · Cited by 32
An overview of PROTACs targeting MDM2 as a novel approach for cancer therapy
Li, H., Cai, X., Yang, X., & Zhang, X. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116506 · Cited by 29
PROTAC Technology as a New Tool for Modern Pharmacotherapy
Kubryń, N., Fijałkowski, Ł., Nowaczyk, J., Jamil, A., & Nowaczyk, A. (2025) · Molecules · doi:10.3390/molecules30102123 · Cited by 30
“…oestrogen receptor modulators (SERMs), work by inhibiting ER activity or blocking its binding to oestrogens. to keep the active site occupied and remain effective However, these approaches have limitations, such as treatment resistance or partial inhibition of ER activity [40]. in treatment.”
New steps on an old path: Novel estrogen receptor inhibitors in breast cancer
Pagliuca, M., Donato, M., D’Amato, A. L., Rosanova, M., Russo, A. O. M., Scafetta, R., Angelis, C. D., Trivedi, M. V., André, F., Arpino, G., et al. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103861 · Cited by 27
Molecular Biology and Therapeutic Perspectives for K-Ras Mutant Non-Small Cell Lung Cancers
Cekani, E., Epistolio, S., Dazio, G., Cefalì, M., Wannesson, L., Frattini, M., & Froesch, P. (2022) · Cancers · doi:10.3390/cancers14174103 · Cited by 27
Liang, X., Ren, H., Han, F., Liang, R., Zhao, J., & Liu, H. (2023) · Medicinal Research Reviews · doi:10.1002/med.21992 · Cited by 31
Acharyya, R. K., Rej, R. K., Hu, B., Chen, Z., Wu, D., Lü, J., Metwally, H., McEachern, D., Wang, Y., Jiang, W., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01521 · Cited by 24
He, Y., Zhu, C., Peng, L., Chen, Y., Zhang, Y., Zheng, Y., & Diao, X. (2024) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2024.101175 · Cited by 25
“The PROTAC vepdegestrant (ARV-471) is a next-generation small-molecule selective estrogen receptor degrader (SERD) for breast cancer that exhibits potent antitumor effects through targeted degradation of the estrogen receptor (ER) [16].”
Hamilton, E. P., Jeselsohn, R. M., Vahdat, L. T., & Hurvitz, S. A. (2025) · Targeted Oncology · doi:10.1007/s11523-025-01137-5 · Cited by 29
Lu, Z., Cao, Y., Zhang, D., Meng, X., Guo, B., Kong, D., & Yang, Y. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00008 · Cited by 25
Targeting micro-environmental pathways by PROTACs as a therapeutic strategy
Liu, J., Peng, Y., Inuzuka, H., & Wei, W. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.07.001 · Cited by 20
Targeted Protein Degradation in Cancer: PROTACs, New Targets, and Clinical Mechanisms
Faryal, B., Abideen, Z. U., Irfan, M., Ahmed, H., Jalilov, F. S., Abduraximova, L., & Ashraf, G. A. (2026) · Biomolecules · doi:10.3390/biom16020325 · Cited by 24
“ARV-471 has shown superior degradation effi-ciency and anti-proliferative activity compared to fulvestrant , the current selective estrogen receptor degrader (SERD) [65].”
Weng, Z., Yu, J., Liao, Y., Zhang, Y., Chen, C., & Chen, W. (2025) · Nano Biomedicine and Engineering · doi:10.26599/nbe.2025.9290128 · Cited by 15
Discovery of the first ataxia telangiectasia and Rad3-related (ATR) degraders for cancer treatment
Huang, L. H., Shao, J., Lai, W., Gu, H., Yang, J., Shi, S., Wufoyrwoth, S., Song, Z., Zou, Y., Xu, Y., et al. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116159 · Cited by 16
Yuan, B., Liu, J., Wu, Y., Chen, M., Lai, Y., Zhao, H., Yang, Z., Zhang, S., & Xin, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00408 · Cited by 19
Betz, M., Massard, V., Gilson, P., Witz, A., Dardare, J., Harlé, A., & Merlin, J. (2023) · Cancers · doi:10.3390/cancers15215169 · Cited by 19
“A patient with an identified D538G mutation and extensive prior therapies showed a confirmed partial response and targeted lesion reduction with ARV-471 [69].”
BackgroundThe emerging role of targeted protein degradation to treat and study cancer
Brodermann, M. H., Henderson, E. K., & Sellar, R. S. (2024) · The Journal of Pathology · doi:10.1002/path.6301 · Cited by 15
“:3) locally advanced or metastatic breast cancer and ARV-110 in metastatic castration-resistant prostate cancer [111 – 114].”
BackgroundCDK9 targeting PROTAC L055 inhibits ERα-positive breast cancer
Chen, W., Wu, Y., Yang, C., Ren, W., Hou, L., Liang, H., Wu, T., Kong, Y., Wu, J., Rao, Y., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116972 · Cited by 16
Mechanisms of Endocrine Resistance in Hormone Receptor-Positive Breast Cancer
Marra, A., Trapani, D., Ferraro, E., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_9 · Cited by 16
PROTAC Beyond Cancer- Exploring the New Therapeutic Potential of Proteolysis Targeting Chimeras
Bhole, R. P., Patil, S., Kapare, H. S., Chikhale, R. V., & Gurav, S. S. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266309968240621072550 · Cited by 15
Whitehurst, B. C., Bauer, M. R., Edfeldt, F., Gunnarsson, A., Margreitter, C., Rawlins, P. B., & Storer, R. I. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00493 · Cited by 18
Ferrari, P., Schiavone, M. L., Scatena, C., & Nicolini, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073438 · Cited by 14
“Vepdegestrant (ARV-471) has been shown to be an anticancer drug that is superior to fulvestrant in xenograft models [169].”
Zaman, S. U., Pagare, P. P., Ma, H., Hoyle, R. G., Zhang, Y., & Li, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00122b · Cited by 15
Omar, E. A., Rajesh, R., Das, P. K., Pal, R., Matada, G. S. P., & Maji, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117034 · Cited by 14
Emerging Therapies for Breast CancerPreprint
Goel, S., & Chandarlapaty, S. (2022) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041333 · Cited by 15
Advancements in PROTAC-based therapies for neurodegenerative diseases
Kong, D., Meng, L., Lin, P., & Wu, G. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2463310 · Cited by 14
Proteolysis-targeting chimeras and their implications in breast cancer
Tecalco-Cruz, Á. C., Zepeda–Cervantes, J., Ramírez‐Jarquín, J. O., & Rojas‐Ochoa, A. (2021) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2021.00060 · Cited by 12
Liu, L., Shi, L., Wang, Z., Zeng, J., Wang, Y., Xiao, H., & Zhu, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839857 · Cited by 13
“Some small molecule PROTACs have also undergone clinical trials (18, 19).”
BackgroundTang, C., Tian, B., Zhang, B., Zhang, Y., Ke, C., Chen, M., Wei, M., Wang, W., Deng, X., Zhang, Q., et al. (2026) · ChemMedChem · doi:10.1002/cmdc.202501111 · Cited by 13
“Second, vepdegestrant retains activity against multiple clinically relevant ESR1 mutations, including Y537S and D538G [41].”
Choi, H.-I., Choi, J., Kim, J. W., Lee, Y. H., Cho, K. H., & Koo, T. (2024) · Molecules · doi:10.3390/molecules29174048 · Cited by 13
“Vepdegestrant facilitates the selective degradation of ER, disrupting the ER signaling pathway that drives tumor growth and offering a promising therapeutic strategy for patients with locally advanced or metastatic breast cancer [13].”
BackgroundHarnessing the Power of Natural Products for Targeted Protein Degradation
Zhu, B., Wu, Z., Shou, Y., Zhao, K., Lu, Q., Qin, J., & Guo, H. (2025) · Medicinal Research Reviews · doi:10.1002/med.22113 · Cited by 12
Peng, R., Liu, X., Chen, C., Guo, R., & Min, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00961d · Cited by 8
The next generation of EGFR inhibitors: a patenting perspective of PROTACs based EGFR degraders
Li, P., Li, B., Yang, N., Xu, T., & Zheng, Z. (2023) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2023.2262176 · Cited by 8
“The phase 1/2 study of ARV-471 for ER + /HER2 − breast cancer with locally advanced or metastatic breast cancer showed that ARV-471 significantly reduced the level of ER by 62% on average and up to 90% at dose levels of 30–700 mg treatment [56].”
BackgroundUpdate Breast Cancer 2023 Part 2 – Advanced-Stage Breast Cancer
Lux, M. P., Hartkopf, A. D., Fehm, T. N., et al. (2023) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-2074-0125 · Cited by 8
Peng, S., Zhang, Q., Tian, H., Zhang, J., Deng, J., Qi, H., Wu, D., Du, T., Zhang, K., Ge, J., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00679 · Cited by 9
Update Breast Cancer 2021 Part 4 – Prevention and Early Stages
Thomssen, C., Fehm, T. N., Stickeler, E., Fasching, P. A., Janni, W., Kolberg‐Liedtke, C., Kolberg, H., Lüftner, D., Müller, V., Schütz, F., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1724-9639 · Cited by 7
“The field of oral SERDs has seen some new developments, such as the use of PROTAC (Proteolysis Targeting Chimera) technology [54].”
Next-Generation Estrogen Receptor–Targeted Therapeutics
Fernando, T. M., Moore, H. M., Wongchenko, M. J., & Metcalfe, C. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061421-013525 · Cited by 10
Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Kolberg‐Liedtke, C., Kolberg, H., Thomssen, C., Müller, V., Fehm, T. N., et al. (2022) · Geburtshilfe und Frauenheilkunde · doi:10.1055/a-1724-9569 · Cited by 6
“None of the patients experienced primary progression [15].”
Palacios, D. S. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01491 · Cited by 5
He, C., Ba, X., Shunatona, H. P., Edwards, J. T., Li, Y., Keller, T. M., Sommer, R. D., Zapf, C. W., & Mortensen, D. S. (2024) · Organic Letters · doi:10.1021/acs.orglett.4c01696 · Cited by 5
Targeted protein degraders from an oncologist point of view: The Holy Grail of cancer therapy?
Ambrosini, M., Fucà, G., Duca, M., Damian, S., Santis, F. D., Corti, F., Cresta, S., de Braud, F., & Nicola, M. D. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103532 · Cited by 5
Advances in combination therapy for the treatment of estrogen receptor positive breast cancer
Liu, L., Zhao, Z., Zou, F., Lu, Y., & Lu, Y. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111451 · Cited by 4
Clinical Translation: Targeting the Estrogen Receptor
Metcalfe, C., & Lauchle, J. (2022) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-11836-4_17 · Cited by 4
PROTACs in gynecological cancers: Current knowledge and future potential as a treatment strategy
Movahed, F., Ourang, Z., Neshat, R., Hussein, W. S., Saihood, A. S., Alarajy, M. S., & Zareii, D. (2024) · Pathology - Research and Practice · doi:10.1016/j.prp.2024.155611 · Cited by 7
Targeted protein degradation: therapeutic potential and challenges of PROTACs and molecular glues
Kim, S., & Jeung, E. (2025) · Journal of Biomedical Translational Research · doi:10.12729/jbtr.2025.26.2.21 · Cited by 3
Mechanisms and Design Principles of Proteolysis-Targeting Chimeras and Their Emerging Applications
Knoll, N., Neamati, N., & Üren, A. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00730 · Cited by 5
Implications of ubiquitination and the maintenance of replication fork stability in cancer therapy
Xia, D., Zhu, X., Wang, Y., Gong, P., Su, H.-S., & Xu, X. (2023) · Bioscience Reports · doi:10.1042/bsr20222591 · Cited by 3
“Moreover, oral PROTACs (ARV-110 and ARV-471) have entered clinical trial of prostate and breast cancer treatment [197,198].”
BackgroundAdvances and challenges of estrogen receptor-targeted agents in breast cancer
Hu, J., Zhong, S., Sun, H., Liu, J., & Fang, W. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01583-9 · Cited by 2
“In preclinical models, vepdegestrant demonstrated superior efficacy over fulvestrant independent of ESR1 mutations, and no ER agonistic activity (Snyder et al. 2021; Qin et al. 2022).”
Kumar, H., & Sobhia, M. E. (2026) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5c07053 · Cited by 4
Discovery of a KLHL41 Ligand for Muscle Specific Protein Degradation
Yim, J., Lee, J., Kim, S., Choi, J., Yoon, S., Cho, H., Jung, S., Yoo, G., Lee, S., Park, H., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-73252-4 · Cited by 5
Nguyen, K. T., Nguyen, H. H., Phùng, H. T. T., Chung, K. L., & Vu, T. Y. (2024) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2024.2308778 · Cited by 2
Su, Z., Yin, S., & Wu, Y. (2024) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.4c06497 · Cited by 2
Targeting Oestrogen Receptor Signalling in Breast Cancer Therapy
Howell, S. J., & Howell, A. (2025) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-70875-6_22 · Cited by 2
The Latest Advancements of the PROTACs Based on CRBN E3 Ligase for Cancer Treatment
Stadnichenko, V. O., Borysko, P., & Tolstanova, G. M. (2025) · Current Pharmacology Reports · doi:10.1007/s40495-025-00409-y · Cited by 2
Targeted Protein Degraders- The Druggability Perspective
Singh, S., & Srivastava, P. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.023 · Cited by 1
Exploring the Role of PROTACs for the Treatment of Breast Cancer
Pannu, A. S., Goyal, R. K., & Goswami, S. (2024) · Springer eBooks · doi:10.1007/978-981-97-5077-1_12 · Cited by 1
Bao, X., Yin, X., Xǔ, J., Zhu, Z., Lu, W., Cai, Y., Dai, R., Zheng, Z., Xu, W., Mei, S., et al. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118199 · Cited by 2
Furuhata, T., Yoshida, K., 凌嘉, 藤., Miyamoto, J., Moriyama, C., Masuda-Ozawa, T., Tsuchiya, H., Saeki, Y., & Okamoto, A. (2026) · Communications Chemistry · doi:10.1038/s42004-026-01895-x · Cited by 1
Contemporary Developments in PROTACs for Cancer Management: An In-Depth Review
Rahaman, S. A., Venkateswarlu, G., Patel, S., Mishra, P. S., Kumar, R., & Parvez, N. (2026) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266384226251013054011 · Cited by 1
A destination-driven framework for nanoparticle-enabled targeted protein degradation
Wang, Y., Xia, X., Xie, S., Tong, F., Liu, W., & Gao, H. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.009 · Cited by 1
“In 2019, the PROTAC molecules ARV-471, targeting the ER, and ARV-110, targeting the AR, advanced into clinical trials, marking a significant milestone in the transition of PROTAC technology from laboratory research to clinical application 55,56 .”
Zhou, W., Ahmed, M., Guan, J., Fox, N. S., Oeh, J., Ingalla, E., Young, A., Tai, L., Giltnane, J., Blake, R. A., et al. (2026) · Cell chemical biology · doi:10.1016/j.chembiol.2026.04.008 · Cited by 2
Update Mammakarzinom 2021 Teil 5 – fortgeschrittenes Mammakarzinom
Lüftner, D., Schütz, F., Stickeler, E., Fasching, P. A., Janni, W., Kolberg‐Liedtke, C., Kolberg, H., Thomssen, C., Müller, V., Fehm, T. N., et al. (2022) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1816-1687 · Cited by 1
“[15] Snyder LB, Flanagan JJ, Qian Y et al.”
InfluentialWITHDRAWN: Targeted protein degradation: A promising approach for cancer treatment
Khan, M. Z. I., Nazli, A., Naz, I., Khan, D., Haq, I., & Chen, J. (2023) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2023.09.004 · Cited by 1
RetractedIdegenerering i IT-bedrifter - åpenhet og nettverks betydning for idégenerering
Liafjell, T. A. (2014) · NORA - Norwegian Open Research Archives
Update Mammakarzinom 2021 Teil 4 – Prävention und frühe Krankheitsstadien
Thomssen, C., Fehm, T. N., Stickeler, E., Fasching, P. A., Janni, W., Kolberg‐Liedtke, C., Kolberg, H., Lüftner, D., Müller, V., Schütz, F., et al. (2022) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-1816-1625
Destruction with a Purpose: Targeted Protein Degradation in Drug Discovery
Martinelli, P., Kofink, C. C., Boeck, G., Weinstabl, H., & Koegl, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch11
Taming the Beast: How to Optimize DMPK–PD Properties of Oral Degraders
Rynn, C., Vyver, A. J. V. D., Walz, A., Cantrill, C., & Wittwer, M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch12
Targeted Protein Degradation – The Story So Far
O’Donovan, D. H., Luh, L. M., & Cromm, P. M. (2022) · Wiley eBooks · doi:10.1002/9783527836208.ch1 · Cited by 1
Update Mammakarzinom 2023 Teil 2 – Brustkrebs in fortgeschrittenen Krankheitsstadien
Lux, M. P., Hartkopf, A. D., Fehm, T. N., et al. (2023) · Senologie - Zeitschrift für Mammadiagnostik und -therapie · doi:10.1055/a-2183-3490
NEW CHEMICAL ENTITIES ENTERING PHASE III TRIALS IN 2023
Lin, D. W., Armstrong, M., Jiang, J. B., del Pozo, J., & Teijaro, C. N. (2024) · Medicinal chemistry reviews · doi:10.1021/mc-2024-vol59.ch18
Metadata
- Authors
- Snyder, L. B., Flanagan, J. J., Qian, Y., Gough, S. M., Andreoli, M., Bookbinder, M., Cadelina, G., Bradley, J., Rousseau, E., Chandler, J., Willard, R., Pizzano, J., Crews, C. M., Crew, A. P., Houston, J., Moore, M. D., Peck, R., & Taylor, I.
- Affiliations
- Arvinas (United States) (US)
- Yale University (US)
- ORCID
- Venue
- Cancer Research
- Published
- 2021-07-01
- Volume
- 81
- Issue
- 13_Supplement
- Pages
- 44-44
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W3180062435
- Cited by
- 126
- References
- 0
- Citations by year
- 2026: 19 · 2025: 29 · 2024: 30 · 2023: 23 · 2022: 20 · 2021: 4
- Type
- conference abstract
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Keywords
- ARV-471, PROTACs, estrogen receptor alpha, E3 ubiquitin ligase, breast cancer, estrogen receptor-positive breast cancer, ESR1 mutations, oral bioavailability, MCF-7 xenografts, patient-derived xenografts
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
